» Articles » PMID: 9485010

Telomerase Activity in Prostate Cancer, Prostatic Intraepithelial Neoplasia, and Benign Prostatic Epithelium

Overview
Journal Cancer Res
Specialty Oncology
Date 1998 Mar 4
PMID 9485010
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Telomerase is a ribonucleoprotein that synthesizes telomeric DNA on chromosomal ends. Telomerase activation has been seen in many immortal cell lines and cancers. Telomerase activity was analyzed in prostate carcinoma; in coexistent prostatic intraepithelial neoplasia (PIN), benign prostatic hyperplasia (BPH), atrophy and normal tissue; and in benign prostate glands. Telomerase activity was detected in 80 of 87 (92%) prostate cancers. Forty-one matched samples (from a total of 32 cases) were available for comparative analysis. The presence of telomerase activity in adjacent PIN, BPH, and normal tissue was correlated with telomerase activity in the malignant epithelium. In these adjacent tissues, telomerase activity was found in 11 of 15 (73%) PINs, 13 of 26 (50%) BPHs, and 1 of 6 (16%) atrophy and 4 of 11 (36%) normal tissues. In contrast to the BPH tissue from cancer-bearing glands, all 16 BPH specimens from patients only diagnosed with BPH were telomerase activity negative. In cancer samples, there was no correlation between telomerase activity and Gleason grade or preoperation prostate-specific antigen level. Our data indicate that telomerase activity is present in most prostate cancers. The high rate of telomerase activity in the benign-appearing areas of these glands may be attributed either to the presence of occult cancer cells or to early molecular alterations of cancer that were histologically inapparent.

Citing Articles

Changes in Gene, Telomere Length, and Mitochondrial DNA in Benign Prostatic Hyperplasia Patients.

Zole E, Baumanis E, Freimane L, Dale R, Leise A, Lietuvietis V Biomedicines. 2024; 12(10).

PMID: 39457663 PMC: 11505421. DOI: 10.3390/biomedicines12102349.


Hormonal regulation of telomerase activity and hTERT expression in steroid-regulated tissues and cancer.

Taheri M, Ghafouri-Fard S, Najafi S, Kallenbach J, Keramatfar E, Atri Roozbahani G Cancer Cell Int. 2022; 22(1):258.

PMID: 35974340 PMC: 9380309. DOI: 10.1186/s12935-022-02678-9.


Race Differences in Telomere Length in Benign Prostate Biopsies and Subsequent Risk of Prostate Cancer.

Rybicki B, Sadasivan S, Chen Y, Loveless I, Gupta N, Chitale D Cancer Epidemiol Biomarkers Prev. 2022; 31(5):991-998.

PMID: 35247880 PMC: 9081233. DOI: 10.1158/1055-9965.EPI-21-1221.


The telomere length landscape of prostate cancer.

Livingstone J, Shiah Y, Yamaguchi T, Heisler L, Huang V, Lesurf R Nat Commun. 2021; 12(1):6893.

PMID: 34824250 PMC: 8617305. DOI: 10.1038/s41467-021-27223-6.


Targeting strategies of adenovirus‑mediated gene therapy and virotherapy for prostate cancer (Review).

Cai Z, Lv H, Cao W, Zhou C, Liu Q, Li H Mol Med Rep. 2017; 16(5):6443-6458.

PMID: 28901490 PMC: 5865813. DOI: 10.3892/mmr.2017.7487.